{"id":40739,"date":"2025-10-21T10:36:34","date_gmt":"2025-10-21T14:36:34","guid":{"rendered":"https:\/\/torontoglobal.ca\/?p=40739"},"modified":"2025-10-21T10:49:08","modified_gmt":"2025-10-21T14:49:08","slug":"mentis-care-in-toronto","status":"publish","type":"post","link":"https:\/\/torontoglobal.ca\/news\/mentis-care-in-toronto\/","title":{"rendered":"SK Biopharmaceuticals and Eurofarma Establish Joint Venture, Mentis Care, In Toronto"},"content":{"rendered":"\n

Mentis Care to develop AI-powered digital health platform for neurological care, anchoring new R&D centre in Canada\u2019s leading innovation hub.<\/em><\/p>\n\n\n\n

TORONTO, October 21, 2025 \u2013 SK Biopharmaceuticals, a global life-sciences company based in South Korea, and Eurofarma, a leading Brazilian multinational pharmaceutical company, today announced the launch of their joint venture, Mentis Care, in Toronto, Canada.<\/p>\n\n\n\n

Mentis Care will focus on research and development of AI-powered digital health solutions for the management of neurological disorders, beginning with technology designed to improve diagnosis and care for people living with epilepsy. The company\u2019s initial platform will combine advanced artificial-intelligence algorithms with real-time electroencephalogram (EEG) data to support early seizure prediction and personalized treatment planning.<\/p>\n\n\n\n

This partnership marks SK Biopharmaceuticals\u2019 and Eurofarma\u2019s first joint digital-health venture in North America, representing a shared commitment to advancing global innovation in central-nervous-system (CNS) disorders through responsible AI and collaborative research.<\/p>\n\n\n\n

\u201cSK Biopharmaceuticals is expanding beyond pharmaceuticals into digital healthcare to open new possibilities in patient care,\u201d said Donghoon Lee, CEO of SK Biopharmaceuticals. \u201cThrough Mentis Care, we will advance toward patient-centered innovation by integrating AI and clinical data to improve epilepsy treatment.\u201d<\/p>\n\n\n\n

\u201cFor Eurofarma, the joint venture represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients\u2019 lives. We are a reference in central nervous system treatments in Latin America, with a broad portfolio of medicines and close relationships with psychiatrists and neurologists. For some years now, we have added digital innovation investments to our R&D activities, and since 2022, we have maintained a small operation in North America. With this new partnership, we will strengthen these fronts in a single move,\u201d says Rodrigo Pereira, Director of Entrepreneurship and Digital at Eurofarma.<\/p>\n\n\n\n

Mentis Care has appointed Hassan Kotob, former Chief Executive Officer of Brain Scientific, as Chief Executive Officer (CEO). Kotob, a veteran healthcare and technology executive with a proven track record across high-growth and emerging technology companies, will lead Mentis Care’s development of a first-of-its-kind, AI- and data-driven platform for predictive brain health \u2014 transforming how seizures and other neurological events are forecast and managed.<\/p>\n\n\n\n

“Mentis Care is an AI-driven digital health company with a mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring,” said Hassan Kotob, CEO of Mentis Care. “By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide.”<\/p>\n\n\n\n

Located in the MaRS Discovery District, Mentis Care joins one of the world\u2019s most dynamic innovation ecosystems, supported by leading institutions such as the University of Toronto, the Vector Institute, and a network of globally recognized research hospitals.<\/p>\n\n\n\n

\u201cOn behalf of the City of Toronto, I am delighted to welcome Mentis Care to our growing community of innovators,\u201d said Olivia Chow, Mayor of Toronto. \u201cToronto\u2019s world-class talent, research institutions, and collaborative ecosystem continue to attract leading global companies that see our city as a partner in advancing health and technology for universal benefit.\u201d<\/p>\n\n\n\n

Toronto Global and Invest Ontario provided advisory support to Mentis Care and its parent companies throughout their North American expansion process.<\/p>\n\n\n\n

\u201cThe decision by SK Biopharmaceuticals and Eurofarma to establish Mentis Care in Toronto is a strong vote of confidence in our region\u2019s leadership in AI and life sciences,\u201d said Stephen Lund, CEO, Toronto Global. \u201cTheir presence will contribute to a growing wave of AI-enabled health innovation that is shaping the future of patient care worldwide.\u201d<\/p>\n\n\n\n

\u201cWe\u2019re proud that SK Biopharmaceuticals and Eurofarma chose Ontario as the base for their next phase of growth,\u201d said Khawar Nasim, CEO of Invest Ontario. \u201cThis expansion reflects the confidence international investors have in the Ontario life sciences community and aligns with our strategy to diversify and deepen partnerships that contribute to a more resilient economy.<\/p>\n\n\n\n

For more information about Toronto Global, please visit www.torontoglobal.ca.<\/a><\/p>\n\n\n\n

Contact<\/h3>\n\n\n\n

Erika Lewis, Manager, Communications 416-271-2641 elewis@torontoglobal.ca<\/p>\n\n\n\n

About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd.<\/h3>\n\n\n\n

SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening\/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology\/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.SKLifeScienceInc.com.<\/a><\/p>\n\n\n\n

Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME’s 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit https:\/\/sk-inc.com\/en\/main\/mainpage.aspx<\/a>. For more information about SK Biopharmaceuticals, visit
www.skbp.com\/eng.<\/a><\/p>\n\n\n\n

About Mentis Care<\/h3>\n\n\n\n

Mentis Care is an AI-driven digital health company transforming neurological care through the first predictive AI platform for brain health. The platform is designed to detect and forecast seizures and other neurological events in real time. By combining advanced machine learning with clinical expertise, Mentis Care aims to give patients and families greater safety, confidence, and peace of mind \u2014 while setting a new global standard in brain health and digital neuromonitoring.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Mentis Care to develop AI-powered digital health platform for neurological care, anchoring new R&D centre in Canada\u2019s leading innovation hub. TORONTO, October 21, 2025 \u2013 SK Biopharmaceuticals, a global life-sciences…<\/p>\n","protected":false},"author":44,"featured_media":40740,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_searchwp_excluded":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[307],"tags":[],"class_list":["post-40739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/posts\/40739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/comments?post=40739"}],"version-history":[{"count":6,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/posts\/40739\/revisions"}],"predecessor-version":[{"id":40750,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/posts\/40739\/revisions\/40750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/media\/40740"}],"wp:attachment":[{"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/media?parent=40739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/categories?post=40739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/torontoglobal.ca\/wp-json\/wp\/v2\/tags?post=40739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}